Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin

MLA

Chien-Yu Lin, et al. “Case Report: Salvage Capmatinib Therapy in KIF5B-MET Fusion-Positive Lung Adenocarcinoma with Resistance to Telisotuzumab Vedotin.” Frontiers in Oncology, vol. 12, Aug. 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.919123.

APA

Chien-Yu Lin, Sheng-Huan Wei, Yi-Lin Chen, Chung-Ta Lee, Shang-Yin Wu, Chung-Liang Ho, Dean C. Pavlick, Po-Lan Su, & Chien-Chung Lin. (2022). Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.919123

Chicago

Chien-Yu Lin, Sheng-Huan Wei, Yi-Lin Chen, Chung-Ta Lee, Shang-Yin Wu, Chung-Liang Ho, Dean C. Pavlick, Po-Lan Su, and Chien-Chung Lin. 2022. “Case Report: Salvage Capmatinib Therapy in KIF5B-MET Fusion-Positive Lung Adenocarcinoma with Resistance to Telisotuzumab Vedotin.” Frontiers in Oncology 12 (August). doi:10.3389/fonc.2022.919123.